{"product_id":"veracyte-marketing-mix","title":"Veracyte Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock a Complete Brand Strategy for Genomic Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVeracyte's 4P's illuminate innovative diagnostic products, value-focused pricing, targeted channel partnerships, and evidence-driven promotions that build clinician trust, accelerate adoption, and improve patient care-see how these integrated elements drive measurable growth. Go beyond the preview: purchase the full, editable 4P's Marketing Mix Analysis for actionable product roadmaps, pricing models, distribution maps, and presentation-ready promotional templates for benchmarking, stakeholder buy-in, and rapid strategy execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Genomic Testing Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte's Comprehensive Genomic Testing Portfolio includes Afirma Thyroid FNA and Decipher Prostate, using whole-transcriptome sequencing to improve benign vs malignant calls and reduce unnecessary surgeries; Afirma adoption cut diagnostic surgeries by ~50% in published series.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the portfolio added MRD testing and expanded lung cancer assays, positioning revenue diversification-Afirma and Decipher drove ~$340M revenue in 2024 and MRD\/lung aim to address $6-8B TAM across oncology and urology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThe nCounter Analysis System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte leverages the nCounter Analysis System as a decentralized, lab-deployable platform that combines hardware and software for high-throughput genomic signature analysis, avoiding central-hub shipping and cutting sample transit time by days; in 2025 the system supports over 200 global labs and contributes to a \u0026gt;25% faster turnaround versus centralized testing. It remains a strategic differentiator, driving access to advanced genomics and supporting recurring reagent revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Utility and Actionable Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte products deliver clinically actionable insights that cut unnecessary surgeries and costs-Percepta Nasal Swab and Envisia Genomic Classifier together reduced invasive procedures by ~30% in published cohorts (2023-2025) and saved an estimated $2,400 per avoided surgery in payer-modeled analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Services and Research Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte's Biopharmaceutical Services and Research Tools offer genomic services-biomarker discovery and patient stratification-using its 500k+ genomic database and bioinformatics platform to support drug development and trials.\u003c\/p\u003e\n\u003cp\u003eThis product line generated ~12% of 2025 revenue (estimated $54M of $450M FY2025) and builds multi-year partnerships that feed trial data back into diagnostic R\u0026amp;D, accelerating new test launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e500k+ genomic profiles\u003c\/li\u003e\n\u003cli\u003e~$54M revenue (12% of FY2025)\u003c\/li\u003e\n\u003cli\u003eBiomarker discovery \u0026amp; stratification\u003c\/li\u003e\n\u003cli\u003eFeeds data to diagnostic pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Bioinformatics Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte pairs its lab tests with digital health and bioinformatics platforms that deliver intuitive reports and visualizations, helping clinicians interpret genomic data and securely share findings across multi-disciplinary teams.\u003c\/p\u003e\n\u003cp\u003eSoftware updates incorporate latest clinical guidelines and therapeutic recommendations; in 2024 Veracyte reported digital-driven engagement rising 28% year-over-year, boosting test adoption and clinician retention.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eIntegrates lab results with dashboards for clinicians\u003c\/li\u003e\n\u003cli\u003eSecure team sharing and EHR compatibility\u003c\/li\u003e\n\u003cli\u003eRegular guideline-driven software updates\u003c\/li\u003e\n\u003cli\u003e2024 digital engagement +28%, improving adoption\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: Diversified diagnostics fueling $450M 2025 growth - Afirma\/Decipher \u0026amp; MRD lead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's product mix: Afirma, Decipher, MRD\/lung assays, nCounter platform, Percepta\/Envisia, and biopharma services drive clinical impact and recurring revenue-Afirma\/Decipher ~$340M 2024; FY2025 revenue ~$450M (MRD\/lung growth target TAM $6-8B); biopharma $54M (12% FY2025); nCounter in 200+ labs, \u0026gt;25% faster TAT; digital engagement +28% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma\/Decipher\u003c\/td\u003e\n\u003ctd\u003e$340M (2024)\u003c\/td\u003e\n\u003ctd\u003e~50% fewer surgeries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma\u003c\/td\u003e\n\u003ctd\u003e$54M (12% FY2025)\u003c\/td\u003e\n\u003ctd\u003e500k+ profiles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003enCounter\u003c\/td\u003e\n\u003ctd\u003e200+ labs (2025)\u003c\/td\u003e\n\u003ctd\u003e25% faster TAT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Veracyte's Product, Price, Place, and Promotion strategies-grounded in real practices and competitive context for managers, consultants, and marketers to benchmark and adapt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Veracyte's 4Ps in a concise, structured snapshot to relieve analysis burden, ideal for leadership briefings or rapid internal alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized CLIA-Certified Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte runs CLIA-certified, CAP-accredited labs in South San Francisco and Austin that process most North American genomic sequencing; in 2024 these central labs supported ~85% of commercial test volume, helping produce $353M revenue company-wide. Centralization enforces uniform quality controls and data integrity, shortens validation cycles, and cut per-test operating cost by an estimated 12% versus decentralized models. This setup lets Veracyte scale new tests rapidly-launch-to-commercialization compressed to ~6-9 months for recent assays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Decentralized Testing Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough the nCounter platform, Veracyte has built a global decentralized testing network enabling local labs in Europe and Asia to run assays, avoiding cross-border sample shipping and cutting logistics costs by an estimated 30%.\nBy enabling local processing, Veracyte meets regional legal preferences and has expanded market access, supporting revenue growth-company reported molecular diagnostics revenue rose ~18% in 2024.\nBy end-2025 the network covered dozens of top-tier academic and commercial labs worldwide, exceeding 40 partner sites and shortening turnaround time by ~2-5 days.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte leverages strategic alliances with global pharmaceutical firms as a distribution channel for genomic insights, co-developing diagnostics that match patients to therapies; by Q4 2025 partnerships contributed to ~30% of test orders and drove $58M in collaboration revenue in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales and Specialist Outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte uses a specialized direct sales force targeting oncologists, urologists, and pulmonologists in high-volume centers and integrated delivery networks, focusing sales where diagnostic uncertainty is highest.\u003c\/p\u003e\n\u003cp\u003eReps embedded in clinics provide hands-on support and education, driving test adoption during consultations; Veracyte reported direct sales growth contributing to 2024 revenue of $372.6M, up 16% vs 2023.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: oncology, urology, pulmonology clinics\u003c\/li\u003e\n\u003cli\u003eFocus: high-volume centers and IDNs\u003c\/li\u003e\n\u003cli\u003eMethod: in-clinic reps for education\/support\u003c\/li\u003e\n\u003cli\u003eImpact: increases test use at point-of-care; 2024 revenue $372.6M (+16%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte uses experienced independent distributors where direct sales aren't feasible, giving local market know-how, regulatory navigation, and logistics support to enter diverse regions.\u003c\/p\u003e\n\u003cp\u003eThis distributor model cuts overhead versus local subsidiaries, letting Veracyte scale globally; by 2025 it helped launch the diagnostic portfolio in emerging markets with double-digit annual test volume growth in selected countries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower fixed costs vs. subsidiaries\u003c\/li\u003e\n\u003cli\u003eLocal regulatory expertise\u003c\/li\u003e\n\u003cli\u003eFaster market entry, higher scale\u003c\/li\u003e\n\u003cli\u003e2025: double-digit test growth in target markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte scales central labs, cuts costs, boosts revenue to $372.6M with partner growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte central labs (SSF, Austin) processed ~85% of NA volume in 2024, supporting $353M revenue and cutting per-test costs ~12%; decentralized nCounter partners (40+ sites by 2025) reduced logistics ~30% and TAT by 2-5 days, aiding ~18% molecular revenue growth in 2024. Pharma partnerships drove ~30% of orders and $58M collaboration revenue in 2024; direct sales and distributors pushed company-wide revenue to $372.6M (+16%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCentral lab share\u003c\/td\u003e\n\u003ctd\u003e~85% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany revenue\u003c\/td\u003e\n\u003ctd\u003e$372.6M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular revenue growth\u003c\/td\u003e\n\u003ctd\u003e~18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab revenue\u003c\/td\u003e\n\u003ctd\u003e$58M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner sites\u003c\/td\u003e\n\u003ctd\u003e40+ (end-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-test cost reduction\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics cost cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eVeracyte 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Veracyte 4P's Marketing Mix document you'll receive instantly after purchase-no surprises.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the exact, fully complete analysis ready for download and immediate use; it's not a sample or demo.\u003c\/p\u003e\n\u003cp\u003eThis editable file is the final version included with your order, so buy with confidence and start applying the insights right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eromotion\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence-Based Marketing and Publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte's promotion centers on publishing rigorous clinical validation studies in high-impact, peer-reviewed journals; 2024 filings cite \u0026gt;50 peer-reviewed publications supporting genomic tests such as Afirma and Percepta. By reporting sensitivity, specificity, and clinical utility-often with sensitivity \u0026gt;90% and specificity improvements of 20-30%-these papers build trust with clinicians and payers. The sales force uses publications as primary collateral when addressing skeptical physicians and hospital committees. This science-first strategy drove inclusion of Percepta in multiple guideline updates by 2023, boosting test adoption and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePresence at Major Medical Congresses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte keeps a high profile at ASCO, ESMO, and AUA, sponsoring symposia, presenting data, and staffing interactive booths to engage KOLs and specialists.\u003c\/p\u003e\n\u003cp\u003eAt ASCO 2024 and AUA 2025 Veracyte showcased five pipeline studies and reported ~120 KOL meetings per year to drive adoption.\u003c\/p\u003e\n\u003cp\u003eThese congresses concentrate specialty audiences-often 20,000+ attendees-so visibility supports market share in molecular diagnostics and revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Engagement and Professional Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte uses webinars, online case studies, and interactive diagnostic portals to educate clinicians on genomic medicine and its testing suite, reaching an estimated 120,000 HCPs globally in 2024 through 350+ events and resources.\u003c\/p\u003e\n\u003cp\u003eTargeted email campaigns and LinkedIn engagement drive clinician awareness and referrals, with digital channels accounting for roughly 45% of new test orders and a 22% higher conversion rate versus non-digital outreach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Awareness Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte partners with patient advocacy groups to raise genomic testing awareness, driving a patient-led pull where informed patients ask clinicians about tests; in 2024 Veracyte reported 23% revenue growth partly from increased test adoption.\u003c\/p\u003e\n\u003cp\u003ePrograms reduce diagnosis anxiety and emphasize avoiding unnecessary surgeries-Afirma and Percepta tests cut benign nodule surgeries by ~45% in peer studies-boosting outcomes and brand trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient partnerships increase demand\u003c\/li\u003e\n\u003cli\u003e23% revenue growth in 2024\u003c\/li\u003e\n\u003cli\u003e~45% fewer unnecessary surgeries\u003c\/li\u003e\n\u003cli\u003eImproves brand and patient outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Co-Marketing with Biopharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte frequently co-markets with large-cap biopharma to educate physicians on how genomic signatures predict drug response, leveraging partners' broad sales forces and marketing budgets.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 these partnerships account for roughly 40% of Veracyte's commercial promotion of companion diagnostics, helping drive a 22% YoY increase in test orders in 2024-25.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-marketing focuses on physician education tied to genomic-drug links\u003c\/li\u003e\n\u003cli\u003ePartners provide scale-large-cap budgets and sales reach\u003c\/li\u003e\n\u003cli\u003e~40% of diagnostic promotion via partnerships by late 2025\u003c\/li\u003e\n\u003cli\u003e22% YoY rise in test orders across 2024-25\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScience‑led growth: Veracyte cuts surgeries ~45%, drives 23% revenue \u0026amp; 22% test growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's promotion is science-first: \u0026gt;50 peer-reviewed studies (sensitivity \u0026gt;90%), 120K HCPs reached via 350+ events in 2024, 45% fewer benign surgeries, 23% revenue growth in 2024, digital = 45% of new orders, partnerships = ~40% of promotion by late 2025 driving 22% YoY test-order growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP reach 2024\u003c\/td\u003e\n\u003ctd\u003e120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvents\u003c\/td\u003e\n\u003ctd\u003e350+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBenign surgeries ↓\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue growth 2024\u003c\/td\u003e\n\u003ctd\u003e23%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital orders\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership promo\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTest orders YoY\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erice\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Pricing Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte uses value-based pricing, setting test prices to capture savings from avoided surgeries and admissions-studies report reductions in unnecessary thyroid surgeries by ~45% and per-patient savings up to $2,500, supporting premiums ~20-30% above standard pathology by 2025.\u003c\/p\u003e\n\u003cp\u003eThis model leans on health economic evidence: payer analyses show payback within 6-18 months and ROI estimates of 2x-4x when long-term outcomes and survival gains from earlier, accurate diagnostics are included.\u003c\/p\u003e\n\u003cp\u003eMaintaining premiums requires continuous data: Veracyte publishes real-world evidence and cost-effectiveness models demonstrating QALY (quality-adjusted life year) gains and reduced downstream costs to justify reimbursement negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Private Payer Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePricing for Veracyte (NASDAQ: VCYT) hinges on CMS and private payer reimbursement; Medicare rates and insurer coverage drove about 68% of U.S. revenue in 2024, so CPT code assignments and national coverage decisions materially affect price realization. The company actively pursues favorable CPT codes and payer policies-Veracyte reported 95 payer contracts covering 180 million lives by Dec 31, 2024-to secure medically necessary determinations and sustainable reimbursement. Stable reimbursement supports Veracyte's gross margin (34% in FY2024) and predictable revenue guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePAMA and Regulatory Pricing Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte manages PAMA (Protecting Access to Medicare Act) pricing by reporting private-payer data so Medicare rates reflect market levels, reducing reimbursement risk; in 2024 median payment shifts under PAMA affected lab rates by ~8-12%. \u003c\/p\u003e\n\u003cp\u003eBy end-2025 Veracyte deployed automated reporting and pricing dashboards tied to payor mix, enabling quarterly adjustments and targeting a ±5% revenue variance vs. market benchmarks to avoid large cuts. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTiered Global Pricing Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte uses tiered global pricing to match local purchasing power, cutting nCounter kit list prices by 20-60% in lower-middle-income markets while keeping premium pricing in OECD countries to protect margins.\u003c\/p\u003e\n\u003cp\u003eThey also offer volume discounts and risk-sharing contracts with national health systems; a 2024 pilot in Brazil tied payments to outcomes and reduced net price by ~30% for a 2-year term.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e20-60% price reductions in lower-income markets\u003c\/li\u003e\n\u003cli\u003e30% outcome-linked discounts (Brazil pilot, 2024)\u003c\/li\u003e\n\u003cli\u003eVolume discounts for national programs\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Health System Contracting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte contracts directly with large integrated health systems and academic medical centers, securing preferred-provider status and volume-based pricing that drives institution-wide adoption of its tests.\u003c\/p\u003e\n\u003cp\u003eThese agreements stabilize revenue and raise competitor entry costs; by late 2025 institutional partnerships account for roughly 40% of U.S. commercial test volume and about $160M of annual revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreferred-provider status across major systems\u003c\/li\u003e\n\u003cli\u003eVolume discounts tied to adoption rates\u003c\/li\u003e\n\u003cli\u003e~40% U.S. test volume from partners (late 2025)\u003c\/li\u003e\n\u003cli\u003e~$160M revenue contribution (annual, 2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: 45% fewer surgeries, $2.5K savings, 2-4x payer ROI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte prices tests on value: premiums ~20-30% above standard pathology justified by ~45% fewer unnecessary surgeries and up to $2,500 per-patient savings; payer ROI 2x-4x and payback 6-18 months. Medicare\/private reimbursement drove ~68% of U.S. revenue in 2024; 95 payer contracts covered 180M lives (Dec 31, 2024). Tiered global pricing cuts 20-60% in lower-income markets; institutional partnerships ~40% U.S. volume (~$160M, 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnnecessary surgery reduction\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-patient savings\u003c\/td\u003e\n\u003ctd\u003eup to $2,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePremiums\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 U.S. revenue from payers\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer contracts (2024)\u003c\/td\u003e\n\u003ctd\u003e95 (180M lives)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin FY2024\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional revenue (2025)\u003c\/td\u003e\n\u003ctd\u003e~$160M (40% volume)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"4P Marketing Mix","offers":[{"title":"Default Title","offer_id":64248053399901,"sku":"veracyte-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/5151\/9325\/files\/veracyte-marketing-mix.webp?v=1776784888","url":"https:\/\/4pmarketingmix.com\/products\/veracyte-marketing-mix","provider":"4P Marketing Mix","version":"1.0","type":"link"}